{
    "clinical_study": {
        "@rank": "121192", 
        "acronym": "IDEAL", 
        "arm_group": [
            {
                "arm_group_label": "IDEAL intervention", 
                "arm_group_type": "Experimental", 
                "description": "Individual cardiovascular risk reduction counseling, coordination with primary care providers to ensure appropriate management of risk factors, and collaboration with mental health staff and social supports. All participants will be offered group exercise classes, and programs will be provided with instruction to provide more healthy meals."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Other", 
                "description": "All participants will be offered group exercise classes, and programs will be provided with instruction to provide more healthy meals."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will determine whether a  program where a health coach works with participants on\n      heart healthy behaviors and treatment of risk factors is coordinated with primary care can\n      reduce overall heart disease risk in people with serious mental illness."
        }, 
        "brief_title": "Intervention Trial to Decrease Cardiovascular Risk in Persons With Serious Mental Illness", 
        "condition": [
            "Cardiovascular Risk Factors", 
            "Serious Mental Illness"
        ], 
        "condition_browse": {
            "mesh_term": "Mental Disorders"
        }, 
        "detailed_description": {
            "textblock": "The objective of this study is to perform a randomized clinical trial (IDEAL) to test a\n      comprehensive cardiovascular risk reduction program for persons with serious mental illness.\n      This trial will enroll adult mental health consumers with at least one cardiovascular risk\n      factor and randomize them to the 18-month IDEAL intervention or control. Intervention\n      participants will receive individual cardiovascular risk reduction counseling, coordination\n      with primary care providers to ensure appropriate management of risk factors, and\n      collaboration with mental health staff and social supports to encourage and motivate\n      participants to reach goals. All participants will be offered group exercise classes, and\n      programs will be provided with instruction to provide more healthy meals. The primary\n      outcome will be the change in estimated cardiovascular risk from the global Framingham Risk\n      Score."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u25aa Age 18 and older\n\n             \u25aa Body mass index at least 25 kg/m2 OR one of the following CVD risk factors:\n\n          -  Hypertension (SBP>= 140mmHg or DBP>= 90mmHg or on antihypertensive medications;\n\n          -  Diabetes mellitus (fasting blood sugar> 125mg/dl or hemoglobin A1c>6.5 or on a\n             hypoglycemic medication);\n\n          -  Dyslipidemia (LDL >130 mg/dl , HDL<40 or total cholesterol >=200 or on a lipid\n             lowering agent);\n\n          -  Current tobacco smoker\n\n               -  Able and willing to give informed consent\n\n               -  Completion of baseline data collection\n\n               -  Willing to accept randomization\n\n               -  Willing to participate in the intervention\n\n        Exclusion Criteria:\n\n          -  \u25aa Cardiovascular event (unstable angina, myocardial infarction) within the past 6\n             months\n\n               -  Serious medical condition which either limits life expectancy or requires active\n                  management (e.g., certain cancers)\n\n               -  Condition which interferes with outcome measurement (e.g., dialysis)\n\n               -  Pregnant or planning a pregnancy during study period.  Nursing mothers would\n                  need approval from physician.\n\n               -  Alcohol or substance use disorder if not sober/abstinent for 30 days\n\n               -  Planning to leave rehabilitation center or clinic within 6 months or move out of\n                  geographic area within 18 months\n\n               -  Investigator judgment (e.g., for concerns about participant or staff safety)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02127671", 
            "org_study_id": "R01 HL112299"
        }, 
        "intervention": [
            {
                "arm_group_label": "IDEAL intervention", 
                "intervention_name": "IDEAL intervention", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Control", 
                "intervention_name": "Control", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 30, 2014", 
        "location": {
            "contact": {
                "last_name": "Joseph V. Gennusa, PhD, RD, LDN", 
                "phone": "410-281-1130"
            }, 
            "facility": {
                "address": {
                    "city": "Woodlawn", 
                    "country": "United States", 
                    "state": "Maryland"
                }, 
                "name": "Johns Hopkins ProHealth Clinical Research Facility"
            }, 
            "investigator": {
                "last_name": "Gail L. Daumit, MD, MHS", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comprehensive CVD Risk Reduction Trial in Persons With Serious Mental Illness", 
        "other_outcome": [
            {
                "measure": "health status with SF-12", 
                "safety_issue": "No", 
                "time_frame": "6 and 18 months"
            }, 
            {
                "measure": "quality of life", 
                "safety_issue": "No", 
                "time_frame": "6 and 18 months"
            }, 
            {
                "measure": "medication adherence", 
                "safety_issue": "No", 
                "time_frame": "6 and 18 months"
            }, 
            {
                "measure": "medication use for cardiovascular risk factors", 
                "safety_issue": "No", 
                "time_frame": "6 and 18 months"
            }
        ], 
        "overall_contact": {
            "email": "jgennus1@jhmi.edu", 
            "last_name": "Joseph V. Gennusa, PhD, RD, LDN", 
            "phone": "410 281 1130"
        }, 
        "overall_contact_backup": {
            "email": "gdaumit@jhmi.edu", 
            "last_name": "Gail L. Daumit, MD, MHS", 
            "phone": "410 614 6460"
        }, 
        "overall_official": {
            "affiliation": "Johns Hopkins University", 
            "last_name": "Gail L. Daumit, MD, MHS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: NHLBI", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "global Framingham Risk Score", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02127671"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Johns Hopkins University", 
            "investigator_full_name": "Gail Daumit, MD, MHS", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "weight", 
                "safety_issue": "No", 
                "time_frame": "6 and 18 months"
            }, 
            {
                "measure": "BMI", 
                "safety_issue": "No", 
                "time_frame": "6 and 18 months"
            }, 
            {
                "measure": "6 minute walk test", 
                "safety_issue": "No", 
                "time_frame": "6 and 18 months"
            }, 
            {
                "measure": "healthy diet", 
                "safety_issue": "No", 
                "time_frame": "6 and 18 months"
            }, 
            {
                "measure": "fasting glucose level", 
                "safety_issue": "No", 
                "time_frame": "6 and 18 months"
            }, 
            {
                "measure": "diabetes mellitus treated to goal (HgBA1c)", 
                "safety_issue": "No", 
                "time_frame": "6 and 18 months"
            }, 
            {
                "measure": "smoking cessation", 
                "safety_issue": "No", 
                "time_frame": "6 and 18 months"
            }, 
            {
                "measure": "blood pressure", 
                "safety_issue": "No", 
                "time_frame": "6 and 18 months"
            }, 
            {
                "measure": "hypertension treated to goal", 
                "safety_issue": "No", 
                "time_frame": "6 and 18 months"
            }, 
            {
                "measure": "total cholesterol", 
                "safety_issue": "No", 
                "time_frame": "6 and 18 months"
            }, 
            {
                "measure": "LDL cholesterol", 
                "safety_issue": "No", 
                "time_frame": "6 and 18 months"
            }, 
            {
                "measure": "HDL cholesterol", 
                "safety_issue": "No", 
                "time_frame": "6 and 18 months"
            }, 
            {
                "measure": "triglycerides", 
                "safety_issue": "No", 
                "time_frame": "6 and 18 months"
            }, 
            {
                "measure": "dyslipidemia treated to goal", 
                "safety_issue": "No", 
                "time_frame": "6 and 18 months"
            }
        ], 
        "source": "Johns Hopkins University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johns Hopkins University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}